依托考昔治疗Ⅲ型前列腺炎临床研究

Clinical research of etoricoxib in treating type Ⅲ prostatitis

目的评价依托考昔治疗Ⅲ型前列腺炎的疗效及安全性。方法采用自身对照及安慰组对照的临床研究方法,共纳入263例受试者,分为对照组和治疗组。对照组口服安慰剂60 mg,每天1次;治疗组口服依托考昔60 mg,每天1次。分别于治疗前、治疗后1周和2周按美国国家健康研究院慢性前列腺炎症状评分(NIH-CPSI)进行评分。结果治疗组治疗前、治疗2周后NIH-CPSI评分与自身及对照组比较,差异均有统计学意义(P<0.01)。治疗期间未发生药物不良反应。结论依托考昔治疗Ⅲ型前列腺炎疗效明显,安全性高。

Objective To observe the efficacy and safety of etoricoxib in the treatment of type Ⅲ prostatitis. Methods By adopting the self control and the placebo control clinical research methods, 263 subjects were divided into the treatment group and the control group. The control group was given with oral placebo 1 ,once daily ,while the treatment group was given with oral etoricoxib 60 mg, once daily. The chronic prostatitis symptom index （IH-CPSI） of National Institutes of Health （NIH） was evaluat- ed before treatment,in 1,2 weeks after treatmenty. Results The scores of NIH-CPSI before treatment and in 2 weeks after treat ment in the treatment group had statistical difference compared with the self control and the placebo group （P〈0.01）. No adverse drug reactions were observed during treatment, Conclusion Etoricoxib has a significant effect with high safety in treating type Ⅲ prostatitis.